MacroGenics reports revenue miss and gets USD 6.33 target for MacroGenics stock

Published on 10/02/2026 at 05:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 32.83 million versus USD 59.14 million expected. MacroGenics stock had a EUR 3.19 prior close on September 30, 2026.

MGNX, US5560991094, Illustration mit AI erstellt.

MacroGenics (US5560991094) reported second-quarter 2026 revenue of USD 32.83 million versus USD 59.14 million expected, while its quarterly earnings per share reached USD 0.31. MarketBeat reported the figures on September 26, 2026, citing MacroGenics results released on August 13, 2026, and also recorded a consensus price target of USD 6.33.

Revenue miss meets earnings surprise

The second-quarter revenue result fell USD 26.31 million short of consensus, a 44.49 percent gap based on the expected figure. At the same time, earnings per share of USD 0.31 exceeded the consensus estimate of a USD 0.08 loss by USD 0.39, creating a mixed operating signal for a clinical-stage biotechnology company.

The financial data for the quarter ended June 30, 2026, show consolidated net income of negative USD 69.64 million and operating cash flow of negative USD 40.75 million. Cash and cash equivalents stood at USD 113.91 million at the end of the quarter, compared with USD 66.52 million at March 31, 2026.

Lean structure supports pipeline spending

At the H.C. Wainwright conference on September 16, 2026, MacroGenics presented a smaller operating structure after selling its embedded manufacturing operation to Bora Pharmaceuticals for USD 120 million. Investing.com reported that management cited more than USD 300 million in partnership revenue over the past year, pro forma cash of USD 327 million and a cash runway through the end of 2028.

The pipeline contains eight assets, with emphasis on antibody-drug conjugates, checkpoint therapies and T-cell engagers. MacroGenics said MGC026 and MGC028 are scheduled for clinical updates at ESMO later in 2026, while MGC030 is moving toward first-in-human studies.

Consensus target remains above Nasdaq quote

The USD 6.33 consensus target cited by MarketBeat stands USD 2.73 above the latest Nasdaq quote, which is a 75.83 percent difference between the two figures. The comparison matters because the quarterly report combines a substantial revenue shortfall with a positive earnings-per-share surprise and a pipeline still dependent on clinical execution.

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies through DART, TRIDENT and antibody-drug conjugate platforms. Its investor materials describe collaborations with Gilead, Incyte and Sanofi, adding partnership milestones to the company's clinical development strategy.

Nasdaq quote and prior close

The latest Nasdaq quote was USD 3.60 on October 1, 2026 at 4:00 p.m. ET, with a 52-week range of USD 1.29 to USD 5.08 and market capitalization of USD 228.8 million. The prior close at Lang & Schwarz was EUR 3.19 on September 30, 2026.